Oncogenic CD44 is essential for pancreatic cancer tumorigenesis: A novel targeted therapeutic strategy

Figure 6 CD44 knockout inhibits the tumorigenic ERK and AKT signaling pathways and enhances the tumor-suppressive p38-p53 signaling axis. A: Kyoto Encyclopedia of Genes and Genomes signaling pathway analysis showed that CD44 knockout affected multiple signaling pathways in pancreatic cancer cells; B-H: Western blotting showed that CD44 knockout reduced the levels of phosphorylated ERK and phosphorylated AKT, but increased the levels of phosphorylated p53, phosphorylated p38, and the DNA-breakage marker γ-H2AX. Data are shown as the mean ± SD of three independent replicates. ^aP < 0.05, ^bP < 0.01 vs CD44-NT in an unpaired t test.